NCT03220477 2025-08-06
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
Clinical Trials
5 trialsNCT04299113 2025-06-26
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02282358 2024-03-08
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT02429375 2022-05-12
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02993991 2017-12-29
PRIMED-001
University Health Network, Toronto
Phase 1 Withdrawn